Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid epidemic

Mallinckrodt Settles U.S. Opioid Drug Probe for $35 million

Nate Raymond  |  July 12, 2017

(Reuters)—Mallinckrodt Plc., one of the largest manufacturers of the generic opioid painkiller oxycodone, will pay $35 million to resolve allegations that it failed to report suspicious drug orders, the U.S. Justice Department said on Tuesday. The deal, in which Mallinckrodt did not admit wrongdoing, marked a record settlement of claims that a drugmaker failed to properly…

Filed under:Legal Updates Tagged with:Mallinckrodt Plcnational opioid addiction epidemicopioid crisisopioid drug probeOxycodone

Missouri Sues Opioid Manufacturers, Joining Two other U.S. States

Nate Raymond  |  June 21, 2017

(Reuters)—Missouri on Wednesday became the third U.S. state to accuse major drug manufacturers of fraudulently misrepresenting the risks of opioid painkillers now at the center of a national addiction epidemic. Missouri Attorney General Josh Hawley said his office filed a lawsuit in a state court in St. Louis against Purdue Pharma LP, Johnson and Johnson…

Filed under:Drug UpdatesPractice SupportProfessional Topics Tagged with:Endo International PlcJohnson and JohnsonMissouri lawsuitnational addiction epidemicOpioid manufacturersopioid painkillersPurdue Pharma LP

U.S. State Attorneys General Probe Opioid Drug Companies

Nate Raymond  |  June 15, 2017

(Reuters)—A bipartisan group of state attorneys general announced on Thursday that they are jointly investigating the marketing and sales practices of drug companies that manufacture opioid painkillers at the center of a national addiction epidemic. Attorneys general from states including Massachusetts, Texas, Illinois and Pennsylvania announced the investigation two weeks after Ohio Attorney General Mike…

Filed under:Legal UpdatesProfessional Topics Tagged with:Allergan Plc.Endo International PlcJohnson and Johnsonnational addiction epidemicopioid drug companiesOpioid probePurdue Pharma LPTeva Pharmaceutical Industries Ltd’s Cephalon

Ohio Sues Five Drug Companies Over Opioid Crisis

Chris Kenning  |  May 31, 2017

CHICAGO (Reuters)—Ohio Attorney General Mike DeWine said on Wednesday his office sued five major drug manufacturers, accusing them of misrepresenting the risks of prescription opioid painkillers and so helping fuel a sky-rocketing drug addiction epidemic. A growing number of state and local governments are suing drugmakers and distributors, seeking to hold them accountable for the…

Filed under:EthicsProfessional Topics Tagged with:Allergan Plc.Endo International PlcJanssen Pharmaceuticals IncOhio lawsuitopioid crisisPurdue Pharma LPTeva Pharmaceutical Industries Ltd’s Cephalon

Rheumatologists Respond to Prescription Opioid Analgesic Crisis

Larry Beresford  |  May 16, 2017

The alarming statistics on prescription opioid overdoses are well known to medical professionals, thanks to the Centers for Disease Control and Prevention (CDC)’s widely cited finding that deaths from opioid analgesics have increased fourfold since 1999.1 Half of all fatal drug overdoses now involve opioids prescribed by a doctor. Meanwhile, a lack of rigorous research…

Filed under:AnalgesicsConditionsDrug UpdatesPain SyndromesPractice Support Tagged with:AddictionanalgesicChronic painepidemicManagementopioidOverdosepatient careprescriptionRheumatic DiseaserheumatologistrheumatologyriskSafetyTreatment

Opioid Use Common Even After Minor Surgery

Lisa Rapaport  |  April 18, 2017

(Reuters Health)—The risk that surgery patients will become chronic opioid users may be similar after minor procedures or major operations, a U.S. study suggests. Three to six months after surgery, new chronic opioid use was about 5.9% with minor operations and 6.5% with major surgery, the study found. The rate was just 0.4% in people…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:ArthritisBack painCarpal Tunnel SyndromeChronic painOpioid abuseOpioidssurgery

U.S. Senator Launches Probe into 5 Top Opioid Drugmakers

Reuters Staff   |  March 29, 2017

(Reuters)—U.S. Democratic Senator Claire McCaskill sought on Tuesday details from the nation’s top opioid drugmakers on their sales and marketing practices, as lawmakers step up efforts to tackle the country’s deadly opioid crisis. The Missouri senator’s investigation comes amid an epidemic of opioid addiction, with 91 Americans dying everyday as a result of overdose, according…

Filed under:Drug UpdatesProfessional Topics Tagged with:Depomed IncepidemicInsys Therapeutics IncJohnson & JohnsonMylan NVopioid crisisOpioid drugmaker probePurdue Pharmasales and marketing practicesU.S. Democratic Senator Claire McCaskill

Pain Management Research Sheds Light on Postsurgical Pain Sensitization, Opioid Risks, Nondrug Interventions

Susan Bernstein  |  March 20, 2017

WASHINGTON, D.C.—Successful management of pain remains a challenge for rheumatologists. Five research abstracts presented at the 2016 ACR/ARHP Annual Meeting in a session titled Pain—Basic and Clinical Aspects offered new insights on pain sensitization, and the risks and effects of various pain therapies. Knee Pain After Surgery Can we predict which patients will have longer-term…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)Managementnondrug interventionopioidPainpatient careQualityResearchrheumatologistrisk

U.S. Senators Question Kaleo’s $4,500 tag on Opioid Overdose Treatment

Ankur Banerjee  |  February 10, 2017

(Reuters)—U.S. Sen. Claire McCaskill (D-Mo.) on Thursday asked Kaleo Pharmaceuticals to justify the more than 550% surge in the price of its device to treat opioid overdoses, becoming the second senator to question Evzio’s $4,500 price tag. Evzio contains the overdose-reversing drug naloxone and can be used in emergencies by people without medical training. Privately…

Filed under:Drug Updates Tagged with:costsdrug pricingDrugsnaloxoneOpioid abuseOpioids

Physicians Asked to Join AMA Efforts to Reduce Opioid Abuse

Mary Beth Nierengarten  |  October 31, 2016

In 2014, the American College of Rheumatology (ACR) was one of 25 healthcare associations invited to participate in an initiative by the American Medical Association (AMA) to reduce the public health epidemic posed by the abuse of prescription opioids.1 The AMA initiative is based on the belief that physicians are professionally obligated to participate in…

Filed under:EthicsProfessional Topics Tagged with:American Medical Association (AMA)Opioid abuseopioid use disordersPrescription drugssubstance abuse disorderstask force

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 9
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences